Caribou Biosciences (CRBU) Current Leases (2022 - 2026)

Caribou Biosciences (CRBU) has 5 years of Current Leases data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Current Leases fell 32.3% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 32.3% YoY) and the FY2025 annual result came in at $1.2 million, down 15.78% from the prior year.
• Current Leases advanced to $1.3 million in Q1 2026 per CRBU's latest filing, from $1.2 million in the prior quarter.
• Across five years, Current Leases topped out at $2.7 million in Q3 2025 and bottomed at $825000.0 in Q1 2022.
• The 5-year median for Current Leases is $1.2 million (2023), against an average of $1.3 million.
• The widest annual swing landed in 2025, when Current Leases soared 128.1%; it then sank 32.3% in 2026.
• Tracing CRBU's Current Leases over 5 years: stood at $966000.0 in 2022, then increased by 24.22% to $1.2 million in 2023, then grew by 18.83% to $1.4 million in 2024, then dropped by 15.78% to $1.2 million in 2025, then rose by 7.16% to $1.3 million in 2026.
• Per Business Quant, the three latest CRBU Current Leases figures stand at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $2.7 million (Q3 2025).

Peer Comparison